NFKB1 and cancer: High proteasome activity, which positively regulates NFκB activity, is often observed in AML patients [227], but inhibiting the proteasome can activate cell stress responses in cancer cells and enable alternative pathways for proteolysis of IκBα, such as the lysosome [41].